$CNPOF Clinches Deal to Grow 17,000 Acres of Hemp in China

September 30, 2019

A Toronto-based cannabis company announced on Tuesday that it had signed an agreement with a Chinese partner allowing the Canadian company to grow and process industrial hemp on 17,000 acres in China.

Pure Global Cannabis, the Canadian company, signed this agreement with a Chinese company called KMT-Hansa Corp. KMT currently holds licenses to grow and process hemp on 17,000 acres in China, and they are teaming up with Pure Global to pull it off.

Under the terms of the agreement, Pure Global will be responsible for providing the technology, know-how and the plant genetics required for the success of the project. Pure Global will also take charge of distribution and sales of all the products that are made during the execution of the joint project.

The Canadian company has also been tasked with designing the extraction, processing and manufacturing facilities that comply with Good Manufacturing Practices (GMP).

Another seller or distributor for the products made can only be sourced once Pure Global declares that it is waiving its right to this component of the business.

KMT-Hansa Corp. will take charge of making sure that all the necessary licenses and permits are secured and maintained with all the relevant Chinese government authorities.

Malay Panchal, the President and CEO of Pure Global, revealed in a press statement that he was excited that Pure Global had managed to be the first Canadian company to secure a partnership that enabled it to put together such a large-scale project in China.

Panchal believes that the entire team at KMT shares Pure Global’s goal of coming up with high-quality agricultural products that are made using the best cutting-edge technology currently available.

This agreement is viewed by both parties as a stepping stone to other bigger international production agreements between the two entities. The two companies are therefore committed to moving quickly to address the needs of a rapidly growing market for CBD products.

Pure Global and KMT plan to sell CBD isolates and consumer products throughout Asia as well as 50 international markets where CBD is legal.

Panchal also revealed that this is an exciting time for Pure Global because they have not only managed to secure the deal with KMT, but have also received a cannabis oils sales license from Health Canada.

Experts believe that partnerships such as those entered into by Pure Global Cannabis and KMT-Hansa Corp. provide impetus to other hemp companies, such as Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) and Earth Science Tech Inc. (OTCQB: ETST), to work harder and increase their international footprint in order to tap the global market for hemp-derived products.

About HempWireNews

HempWireNews (HWN) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HNW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWireNews (HWN) is where HEMP news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.HempWireNews.com

Please see full terms of use and disclaimers on the HempWireNews website applicable to all content provided by HNW, wherever published or re-published: https://www.HempWireNews.com/Disclaimer

Do you have a questions or are you interested in working with HWN? Ask our Editor

HempWireNews (HWN)
Denver, Colorado
www.HempWireNews.com
303.498.7722 Office
Editor@HempWire.net

$POAI Repayment or Extension of Promissory Notes

MINNEAPOLIS, Sept. 30, 2019 — Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) today announced that its secured promissory notes that were due September 28, 2019 have been repaid or extended. On September 27, 2019, the Company repaid the remaining principal and interest balance of $478,590 on one of such notes. On the same date, the Company obtained a new investment of $700,000 from a private investor in exchange for a new 8% secured promissory note due on March 27, 2020 with an original principal amount of $847,500. The Company also issued 88,574 shares of common stock and a 682,368 share warrant to the new investor.

In addition, on September 27, 2019, the Company amended the other outstanding note to extend the maturity date from September 28, 2019 to December 31, 2019. The outstanding principal amount of the note was increased by $120,000 to a current principal amount of $1,789,104, and the Company issued 150,000 shares of common stock to the investor in connection with certain amended terms.

About Predictive Oncology Inc.

Predictive Oncology Inc. (NASDAQ: POAI) operates in two business areas: first, applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for patients and clinicians as well as clients in the pharmaceutical, diagnostic, and biotech industries, and second, production of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal.

Forward-Looking Statements

Certain of the matters discussed in the press release contain forward-looking statements that involve material risks to and uncertainties in the Company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include (i) risks related to the recent merger with Helomics, including the fact that the combined company will not be able to continue operating without additional financing; possible failure to realize anticipated benefits of the merger; costs associated with the merger may be higher than expected; the merger may result in disruption of the Company’s and Helomics’ existing businesses, distraction of management and diversion of resources; and the market price of the Company’s common stock may decline as a result of the merger; (ii) risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; and (iii) other risks and uncertainties relating to the Company that include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; sales cycles that can be longer than expected, resulting in delays in projected sales or failure to make such sales; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; Predictive Oncology’s ability to implement its long range business plan for various applications of its technology; Predictive Oncology’s ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of Predictive Oncology’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the SEC, which are available for review at www.sec.gov. This is not a solicitation to buy or sell securities and does not purport to be an analysis of Predictive Oncology’s financial position. See Predictive Oncology’s most recent Annual Report on Form 10-K, and subsequent reports and other filings at www.sec.gov.

Contact
Bob Myers, Predictive Oncology Inc.
651-389-4800

$YGYI Pennsylvania Governor Support for Recreational Marijuana Legalization

September 30, 2019

In a press conference on Wednesday, Tom Wolf, Pennsylvania Governor accompanied by Lt. Gov. John Fetterman, announced his support for the legalization of adult-use recreational marijuana. In his announcement, he included the final report from Lt. Governor John Fetterman’s statewide tour on recreational marijuana legalization. He also proposed the next steps to be taken after reviewing the input submitted by the citizens from the 67 counties who attended their listening sessions or reverted via their online platform.

In his announcement, Governor Wolf said that Lt.Governor Fetterman fulfilled his promise of touring all the 67 counties in Pennsylvania to get the opinion of the citizens regarding the legalization of adult-use recreational marijuana. Moreover, the majority of the feedback received was in favor of recreational marijuana legalization.

Lt. Governor John Fetterman invited the public, media companies and local officials to the tour stops in each county, where the attendees indicated their interest in the bill by a show of hands.

The report comprises of two parts. The first part looks at the volume of messages sent to the online platform hosted on the governor’s website, the comments made on the platform and comment cards collected at the tour stops, as well as any additional message received by the Lt. Gov Fetterman in other formats.

During the announcement, the Lt. Governor voiced his appreciation for the Pennsylvania citizens who attended his tours and those who submitted their comments either physically or online. He also assured the Pennsylvanians that they will do their best to bring into effect the proposed changes.

Apart from announcing the report, the Pennsylvania Governor and Lt. Governor called for the legislature to get a bill that decriminalizes non-violent and cannabis-related offenses to the governor’s desk. They also announced that they are seeking justice by expunging non-violent and small cannabis-related crimes convicted in the past. Finally, they are asking the General Assembly to debate and pass the bill legalizing recreational marijuana.

Since the majority of Pennsylvania residents are in favor of recreational marijuana legalization, Governor Wolf says that he is looking forward to accomplishing many missions together. This includes the criminal justice reform that he is proposing as it will positively affect the people of Pennsylvania.

In his final remarks, Governor Wolf expressed his gratitude to Lt. Gov. John Fetterman for touring the 67 counties and conducting the research. More gratitude was directed towards the Pennsylvanians who attended the tour stops, wrote messages or called the headquarters to voice their opinion.

Analysts are of the view that industry players like Youngevity International Inc. (NASDAQ: YGYI) and Cannabis Strategic Ventures Inc. (OTCQB: NUGS) will only be happy for the people of Pennsylvania once a legalization bill is passed and signed off.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

$TGODF Advances Within Competitive Canadian Cannabis Space

$OGI Comparing Leading Cannabis Stocks in a Stockpicker’s World

$POAI Bringing Precision Medicine Tools to Physicians

$PBIO VIDEO Update w/ Shelly Craft of SNNLive @StockNewsNow

Pressure BioSciences, Inc. (OTCQB: PBIO) is engaged in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry, according to the company’s website (click here: www.pressurebiosciences.com). SNNLive caught up with Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc. at RHK Capital’s 2019 Disruptive Growth Company Showcase in New York City, NY, and they discuss the following topics:

– Overview of Pressure BioSciences, Inc.

– Update since our last interview (click here)

– Focus on CBD Market

– Adoption rate for new product

– Growth drivers for 2019-2020

For more information about Pressure BioSciences, Inc., please visit: www.pressurebiosciences.com

The interview may contain forward looking statements about Pressure BioSciences, Inc. See Pressure BioSciences’ periodic filings with the Securities and Exchange Commission for more complete information.

Please read our full disclosure here.

$GGBXF Jann Parish Named to Forbes CMO Next List

COLUMBUS, OH, Sept. 26, 2019 – Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) (“GGB” or “the Company”) is pleased to announce that Jann Parish, Chief Marketing Officer, has been named to the Forbes CMO Next list. The list is comprised of 50 individuals who are leading the way as disruptive chief marketers.

Through qualitative research tapping into the expertise of industry watchers as well as Forbes‘ editorial industry knowledge, the list features 50 people who have reached the highest-level marketing position within a given company and who are driving brand and business growth.

“I am honored and humbled to receive this recognition,” said Jann Parish, CMO of Green Growth Brands. “I am thrilled to be applying my expertise to the cannabis and CBD industries. At Green Growth Brands, we look at this moment in time as an opportunity to reinvent the way consumers view and interact with products that have very complicated histories. For Forbes to be considering our industry as part of this award speaks to the progress we have already made.”

“Jann has experience growing and redefining some of the most iconic global brands,” said Peter Horvath, CEO of Green Growth Brands. “Her vision and leadership are pivotal to our strategy— creating the new standard of cannabis and CBD consumer experiences. We are thrilled for her and the well-deserved recognition.”

Through Parish’s leadership GGB has opened over 130 Seventh Sense CBD shops across the U.S., grown Seventh Sense’s digital reach, prepared for the October launch of new CBD brand, Green Lily and increased sales and margin figures in its Nevada The+Source dispensary business by double digits.

About Green Growth Brands Inc.
Green Growth Brands creates remarkable experiences in cannabis and CBD. Led by CEO Peter Horvath and a leadership team of consumer-focused retail experts, the company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and Meri + Jayne. The Company also has a licensing agreement with the Greg Norman™ Brand to develop a line of CBD-infused personal care products designed for active wellness. Already driving the strongest sales per square feet in the cannabis industry, GGB is expanding its cannabis operations throughout the U.S its CBD presence at ShopSeventhSense.com, in malls across the country, at DSW and Abercrombie & Fitch stores—and that’s just the beginning. Learn more about the vision at GreenGrowthBrands.com.

Cautionary Statements:

Certain information in this news release constitutes forward-looking statements under applicable securities law. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “intend”, “forecast” and similar expressions.  Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical and recreational marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the marijuana industry in the United States, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; currency and interest rate fluctuations and other risks, including those factors described under the heading “Risks Factors” in the Company’s Annual Information Form dated November 26, 2018, which is available on the Company’s issuer profile on SEDAR.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this release, including, but not limited to, the Company’s ability to execute on its growth strategy, the Company’s vision to become a multi-state operator with retail stores exceeding certain financial thresholds is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

This announcement does not constitute an offer, invitation or recommendation to subscribe for or purchase any securities and neither this announcement nor anything contained in it shall form the basis of any contract or commitment. In particular, this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal.

The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available.

$CNPOF $RIV.V Announces Results of Annual General and Special Meeting of Shareholders

TORONTO, Sept. 26, 2019 – Canopy Rivers Inc. (“Canopy Rivers” or the “Company“) (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, today announced the voting results from its annual general and special meeting of shareholders (the “Meeting“) held today.

32,117,069 of the Company’s issued and outstanding subordinated voting shares (each carrying one vote per share) and 36,468,318 of the Company’s issued and outstanding multiple voting shares (each carrying 20 votes per share), representing 86.14% of the votes attached to all outstanding shares of the Company, were represented in person or by proxy at the Meeting.

Shareholders voted in favour of each of the items of business before the Meeting, including the election of each of the director nominees to serve until the Company’s next annual shareholders’ meeting or until his or her successor is duly elected or appointed. The results are set out below:

For detailed voting results on each matter, please refer to the Company’s Report of Voting Results available under the Company’s profile on SEDAR at www.sedar.com.

About Canopy Rivers:
Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.

$TGODF UK Experts Want Medical Marijuana Free for All

September 26, 2019

The UK government has legalized the use of medical marijuana; however, accessing it is next to impossible. This has prompted professors, doctors, health experts, and politicians to sign letters petitioning the government to make medical marijuana free to all patients. To access medical marijuana for free, patients have to present a prescription from the NHS (National Health Service), which serves as the United Kingdom’s comprehensive, universal, and free-at-the-point-of-service system of medication.

It is legal to prescribe medical cannabis under particular conditions on the NHS system; however, there exist several restrictions and obstacles that hinder specialists from prescribing medical marijuana treatment to patients. The letter signed by the pharmacists, health experts, and members of parliament appeals to the UK Health Secretary Matt Hancock to lift these restrictions. The Members of Parliament representing the Liberal Democrats and Labour have also signed a letter to the Prime Minister, Boris Johnson, appealing to him to intervene for the patients who are unable to access medical marijuana prescriptions.

Doctors and politicians are ready to change the highly restrictive measures administered by the UK government regarding legal access to medical cannabis. The UK government system governing access to medical marijuana does not give access to those patients who highly need it, thus causing unnecessary deaths and addiction to painkillers which could be avoided by treating the patient with medical cannabis.

In their letter to Mr. Hancock, the health experts argue that the failure of the medical and pharmacy professions to embrace medical cannabis is the leading cause of death from conditions that could be prevented, such as epilepsy.

A recent study by Public  Health England concludes that a quarter of the population, ‘mainly adults’ consume strong painkillers, sleeping aids and antidepressants. The conditions forcing them to take these medications could be effectively and safely treated using medical marijuana.

Health experts in the UK want these restrictions lifted because it would make it easier for the doctors to prescribe medical cannabis for treatment using the NHS system. They want Hancock to scrape off the rule requiring a senior doctor to sign off on a prescription and allow a general specialist to write medical marijuana prescriptions. Besides, they want the laws governing the importation of medical marijuana simplified.

The proposed changes to medical marijuana could improve the lives of many patients because with a prescription from the medical provider; patients can access medical cannabis freely. Lack of access to medical cannabis prescription forces patients to seek the help of private caregivers who are very expensive; forcing the patients to turn to the use of unregulated weed for relief.

For the long term effect of free medical marijuana to be seen, professors, health experts and MPs advocate for the training of doctors on medical cannabis treatment and the process of prescribing. Medical cannabis should be prescribed to patients suffering from chronic pain, epilepsy, cancer, multiple sclerosis, depression and insomnia.

In response to the letter, NICE (National Institute for Health and Care Excellence) is opposed to the use of medical marijuana, citing lack of enough clinical evidence.

Industry analysts think that marijuana industry actors like The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) and The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTCQX: SPRWF) would wish that UK patients get as much access to Medical marijuana as those in Northern America.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

$PBIO Patented PCT Platform Highlighted in 10 Separate Presentations

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced that its patented pressure cycling technology (“PCT”) platform was prominently featured at the International Human Proteome Organization World Congress (“International HUPO”) in no less than ten separate presentations from scientists affiliated with seventeen leading research institutions worldwide. “We believe the unique value provided by our PCT platform for cancer research and diagnostics, which was broadly highlighted across ten presentations at this important international human protein conference, will help to accelerate awareness and adoption for our unique PCT sample preparation platform across multiple large and growing markets. Subsequently, we believe this increased awareness and conversion into adoption will result in increased sales of our PCT instruments and consumables in Q4 2019 and beyond,” Pressure BioSciences Global Director of Sales & Marketing Roxana McCloskey stated in the news release.

To view the full press release, visit http://nnw.fm/b8P6s

About Pressure BioSciences Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://nnw.fm/PBIO

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$OGI 3 Brand-Name Cannabis-Infused Beverage Stocks You Need to Know

The biggest marijuana day of the year is exactly three weeks away. On Oct. 17, 2019, marking the one-year anniversary since recreational marijuana sales commenced in Canada, rules governing the sale of derivative pot products will officially go into effect. However, new products won’t hit dispensary store shelves until about two months later.

Derivatives are non-dried-flower marijuana products. Examples include edibles, concentrates, vapes, topicals, and nonalcoholic infused beverages. Prior to Oct. 17, 2019, only dried cannabis flower, cannabis oil, and sublingual sprays were given the green light by regulatory agency Health Canada.

The excitement surrounding the launch of derivatives is easy to wrap your hands around as an investor or business operator in the cannabis space for one simple reason: the margins are juicier. In select recreationally legalized U.S. markets, the oversupply and eventual commoditization of dried flower has led to a steady decline in per-gram dried cannabis pricing, as well as margins. That oversupply concern simply doesn’t exist in the derivatives space.

Furthermore, derivatives tend to speak to a newer generation of marijuana-product consumers. With tobacco health concerns better known after decades of research, younger pot users prefer consumption options that don’t involve smoking dried flower. That’s where derivative pot products come into play.

Among the many alternative consumption options available, perhaps none has attracted more attention from brand-name cannabis stocks and ancillary players than infused beverages. Though there are no shortage of companies angling for their piece of the pie, the following three cannabis stocks are the ones you’ll want to know.

Canopy Growth

Canopy Growth (NYSE:CGC) is not only the largest marijuana stock in the world by market cap, but it’s liable to be one of the largest players in the infused beverage business. That distinction is the result of a massive equity investment from Corona and Modelo beer-maker Constellation Brands (NYSE:STZ) that closed in November.

The investment made by Constellation gave the company a 37% stake in Canopy Growth. Obviously, Constellation sees more in Canopy than just partnering up on a line of infused beverages; otherwise, it wouldn’t have taken a cumulative $4.2 billion equity stake and purchased approximately $150 million in convertible notes between Oct. 2017 and Nov. 2018. Nevertheless, Constellation Brands is looking for ways to naturally expand its reach into other vice industries, and cannabis is a natural evolution, according to its management team.

This partnership will allow Constellation and Canopy to bring their unique perspectives to the table in creating a line of infused cannabis beverages. Namely, Canopy will be leaned on for its expertise in cannabis, as well as its branding strengths and ability to land substantive supply deals. Meanwhile, Constellation Brands has a history of successful marketing, product innovation, and boasts deep pockets.

It’s unclear how much of a needle mover infused beverages will be for Constellation in the quarters to come, but it should be a difference maker for Canopy Growth.

OrganiGram Holdings

The thing about the cannabis industry is that businesses don’t need to be the size of Canopy Growth to be wildly successful at certain niches. New Brunswick-based OrganiGram Holdings (NASDAQ:OGI), which sports a roughly $650 million market cap, is a perfect example.

OrganiGram is focused on a slew of derivative options. It’s one of four suppliers chosen by PAX Labs for the Era vape device, and the company has spent 15 million Canadian dollars on a line of fully automated equipment that will allow for the production of 4 million kilos of infused chocolates each year. But the most intriguing aspect of OrganiGram’s derivatives line might just be its nano-emulsion technology that’s focused on beverages.

Earlier this year, OrganiGram announced that it had developed a nano-emulsification technology that can be added to beverages to speed up the process by which cannabinoids take effect. The company plans to introduce this technology first as a powder that users can add to an infused beverage of their choosing.

However, OrganiGram has also made clear that it would like to develop a line of infused cannabis beverages with this proprietary technology already built in. It’s been actively looking for a beverage partner to help develop and market a nano-emulsification beverage product, and I’d be genuinely surprised if it failed to find one relatively soon.

HEXO

A third brand-name Canadian pot stock that you’ll want to closely monitor as infused beverages begin to roll out is Quebec-based HEXO (NYSE:HEXO).

Even though Constellation’s $190 million equity investment into Canopy in Oct. 2017 marked the first foray of a major company into the cannabis space, it’s the joint venture between HEXO and Molson Coors Brewing (NYSE:TAP), announced on Aug. 1, 2018, that truly signaled a definitive focus on marijuana products between a brand-name company and a pot stock.

The joint venture, known as Truss, is majority-owned by Molson Coors (57.5% to 42.5%). As with the Constellation-Canopy equity investment, Molson and HEXO plan to lean on each other’s expertise to market their infused beverages. HEXO has keen knowledge of growing and processing marijuana, as well as landing major supply deals. Meanwhile, Molson Coors understands how to market beverage products and scale production.

Because Molson Coors is generating more than $10 billion annually in sales, it’s unclear how much of an impact infused beverages will have on its top or bottom line. But given its persistent decline in beer market share in Canada, partnering with a brand-name cannabis stock was a must for Molson Coors.

HEXO, on the other hand, should see an even more impactful increase on its sales from beverages than Canopy Growth. Look for 2020 to be a year of impressive sales and margin expansion for HEXO.

$GNPX Featured in Audio Publication Discussing New Research on Breast Cancer Treatment

NEW YORK, Sept. 26, 2019 — via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers.”

To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/wd8LJ

To read the full editorial, visit: http://nnw.fm/n7Txk

Treatment for breast cancer varies, based on both the patient’s circumstances and type of cancer. The development of treatments to suppress or even eliminate cancer has led to a high survival rate in wealthy countries, with around 85% of patients in the United States and United Kingdom surviving for at least five years from diagnosis. But even in these countries, survival depends upon the exact form of the cancer, how far it has progressed and whether a treatment has been developed for that particular form. Cancer is a difficult disease to defeat, and survival can depend upon the ability of scientists to counter a specific genetic defect in a specific set of cells.

Because cancers are so varied and challenging to tackle, every individual win is worth celebrating. That’s why recent news relating to triple-negative breast cancer (TNBC) has brought excitement both for independent researchers and for Genprex Inc. (NASDAQ:GNPX), a clinical-stage, gene-therapy company whose tumor suppressor candidate 2 (TUSC2) was found to prevent tumor growth in TNBC.

About Genprex Inc.

Genprex Inc. is a clinical-stage, gene-therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell-signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Visit the company’s web site at www.genprex.com or follow Genprex on Twitter at twitter.com/genprex, Facebook at facebook.com/genprexinc and LinkedIn at linkedin.com/company/genprex.

About NetworkNewsAudio

NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) can assist your company by cutting through the overload of information in today’s market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.

For more information, visit: www.NetworkNewsAudio.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications:

NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com

$YGYI Closes $8.3M Public Offering; Launches HEMP FX Brand in Japan

$TGODF Confirms Robust Demand for Premium Organic Cannabis

• The Green Organic Dutchman produces high-quality, organic cannabis for the medicinal and recreational adult use markets from purpose-built, state-of-the-art facilities
• The company has confirmed higher demand for premium organic cannabis
• TGOD has also announced positive results from its pharmacokinetic study of innovative cannabinoid technology

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is an international, premium organic cannabis company based in Mississauga, Ontario. The company produces high-quality, organic medical and recreational adult use cannabis using organic craft growing principles. TGOD plans on commercializing organic cannabinoid dissolvables in Canada beginning in December 2019 under the TGOD-Infusers line of premium cannabis products, and results from a recent study have given support to that move. Additionally, TGOD was able to report strong demand for its premium organic cannabis following its Ontario launch and fast-tracked shipments.

Following its Ontario launch and fast-tracked shipments, TGOD reported that there is a strong demand for its premium organic…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://nnw.fm/TGODF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$SRAX to Present at the 5th Annual B. Riley Consumer & Media Conference

LOS ANGELES, Sept. 25, 2019 — SRAX, Inc. (NASDAQ: SRAX), a digital marketing and consumer data management technology company, is scheduled to present at the 5^th Annual B. Riley Consumer & Media Conference on Thursday, October 3, 2019, at the Sofitel Hotel in New York City.

CEO Chris Miglino will participate in a fireside chat with analyst Mike Crawford on October 3^rd at 1:00 p.m. ET and will host one-on-one meetings with investors throughout the day. To schedule a meeting please contact your B. Riley representative.

About SRAX
SRAX (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels. Monetizing its data sets, SRAX is growing multiple recurring revenue streams through its various platforms. Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data thereby offering everyone in the Internet ecosystem choice, transparency, and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury, and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information on SRAX, visit www.srax.com

CONTACT: Kirsten Chapman /Mary Magnani, LHA Investor Relations, 415.433.3777, srax@lhai.com

$PBIO Proprietary Technology Platform Identified as Key Cancer Biomarker Research Element

• Independent research carried out by Chinese and Australian scientists shows that the Pressure BioSciences Pressure Cycling Technology (PCT) platform is excellent for the processing of preserved (formalin-fixed paraffin-embedded, or FFPE) and fresh frozen biopsy tissues, which are considered invaluable for discovering cancer biomarkers
• Such tissues play a pivotal role in cancer research and may potentially contribute to the development of therapies and prevention protocols
• Cancer research is one of the more rapidly growing sectors making use of PBIO’s technology; to prepare for further expansion in the future, the company has appointed a new, highly experienced chief financial officer
• The company recently announced that Daniel J. Shea has joined the team as chief financial officer and senior vice president, in anticipation of growth

Pressure BioSciences Inc.’s (OTCQB: PBIO) novel and powerful Pressure Cycling Technology (PCT) platform has performed excellently during the processing of preserved (FFPE) and fresh frozen biopsy tissue samples for the discovery of cancer biomarkers, as indicated by two recently published scientific articles about the technology’s performance.

Independent teams of scientists from China and Australia led the research, and their data suggest that the Pressure BioSciences technology could potentially be used in the clinical diagnostic process based on the cancer biomarkers, as the company noted in…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://nnw.fm/PBIO

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$OGI One of the Largest Licensed Cannabis Producers in Canada

Sep 25, 2019

$LXRP Powdered Formulation of CBD-Rich Hemp Oil Now Available to US Consumers

$GGBXF to Report Results, Host Earnings Conference Call for Q4 and Fiscal Year 2019

$GNPX Featured in Publication on Advances in Potential Breast Cancer Treatments

NEW YORK, Sept. 25, 2019 — via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company for private and public entities.

To view the full publication, titled “Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers,” visit: http://nnw.fm/pNKm2

About Genprex Inc.

Genprex Inc. is a clinical-stage, gene-therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell-signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Visit the company’s web site at www.genprex.com or follow Genprex on Twitter at twitter.com/genprex, Facebook at facebook.com/genprexinc and LinkedIn at linkedin.com/company/genprex.

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications:

NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com

$GNPX Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

$GGBXF Why the Magic Mushroom Story Could be as Big as the Cannabis Boom

Palm Beach, FL – September 24, 2019 – As cannabis legalization spreads, another drug may soon follow in its footsteps — psilocybin mushrooms.  In fact, analysts argue mushrooms may hold untapped medical properties that could be used to help treat depression and addiction.  Better, the U.S. FDA already granted “breakthrough status” to COMPASS Pathways’ psilocybin-assisted therapy in October 2018, which allows the FDA assist in the development of a promising drug to treat serious illnesses.  In addition, researchers at New York University found psilocybin mushrooms caused a “rapid and sustained” reduction in anxiety and depression in patients with cancer, as reported by the Financial Post.  Psychiatrists at Johns Hopkins University even found that mushrooms can help with smoking cessation, and another study found it can assist with alcohol dependence.  That’s all opening a wide range of opportunity for companies that have already established launching cannabis products including The Yield Growth Corp. (OTCQB:BOSQF) (CSE:BOSS),  Charlotte’s Web Holdings Inc. (OTCQX:CWBHF) (CSE:CWEB), Green Growth Brands Inc. (OTCQB:GGBXF) (CSE:GGB), GW Pharmaceuticals (NASDAQ:GWPH), and Tilray Inc. (NASDAQ:TLRY).

The Yield Growth Corp.(CSE:BOSS) (OTCQB:BOSQF) BREAKING NEWS:The Yield Growth Corp. just announced that its newly created subsidiary Flourish Mushroom Labs Inc. entered into an agreement on September 20, 2019 to purchase nine recipes which include edible mushrooms as a key ingredient.  The acquisition is from a consortium of creators of the formulas, including a chemical engineer, a holistic health coach and food chemist, and a chef, and is expected to be completed within 30 days. The formulas and know-how to be acquired relate to formulations that may be used to create ready to eat packaged food products or packaged food products that may be mixed with mushroom varietals of the consumer’s choice. The formulations are Chai latte green tea flavor mushroom tea, Lemon grass, lemon and hibiscus lemon mushroom tea, Veggie mix for mushroom soup, Miso dehydrated seaweed mix for mushroom soup, Hot cocoa, coconut sugar and vanilla flavored mushroom elixir, Pumpkin spice mushroom elixir, White chocolate truffle relaxing formula, Dark chocolate truffle energy formula, and Wild mushroom bliss ball with coco and dried fruits.

Yield Growth also announced its entry into the edible mushroom market with an agreement to acquire 30% of Absolem Health Corp., owner of One Up Pure Energy, which has edible mushroom snacks registered with Health Canada.  Now Yield has set up Flourish Mushroom Labs as a wholly owned subsidiary and this library of 9 mushroom formulas is its first announced acquisition.  “These healthy edible mushroom formulations have the potential to be made with psilocybin mushrooms in jurisdictions where magic mushrooms are legal,” says Yield Growth CEO Penny Green, “We are pleased to add mushroom formulas to our extensive catalogue of formulas to our cannabis formulas which are at various stages of commercialization.”

Other related developments in Yield Growth’s industry include: 

Charlotte’s Web Holdings Inc.(CSE:CWEB)(OTCQX:CWBHF) just announced that Russell Hammer has joined the Company as Chief Financial Officer, effective tomorrow, August 15, 2019.  Mr. Hammer, who has most recently served as an advisor in private equity investments, brings more than 30 years of finance experience in the retail, tourism and technology sectors. With his experience leading multi-billion-dollar multinational companies, he is the latest top-tier executive to join Charlotte’s Web as the Company accelerates its growth and evolution into a global consumer packaged goods (“CPG”) brand. Mr. Hammer replaces Rich Mohr, who as CFO has overseen the Company’s successful transition to a publicly traded company and market leader in hemp CBD products.  “Russ’s appointment aligns perfectly to support the Company’s evolution over the past few years from an early stage organization to a leading public company, into its next phase transitioning to a global CPG company. His breadth of international finance experience across a range of industries, as well as expertise in building operational infrastructure, applying forward-looking analytics, M&A, and accessing capital markets will help us scale the business in a financially stable way,” said Deanie Elsner, CEO of Charlotte’s Web.

Green Growth Brands Inc.(CSE:GGB)(OTCQB:GGBXF) just announced that it will open 100^th Seventh Sense Botanical Therapy mall-based shop. The first Seventh Sense shop opened in early February.  “This is a huge milestone for Green Growth Brands and Seventh Sense,” said Peter Horvath, CEO of Green Growth Brands. “We believe we have created the largest and most valuable network of brick and mortar CBD shops in the country.” Seventh Sense shops retail high-quality botanical therapy CBD-infused personal care and beauty products at affordable prices. The product offering includes over 100 SKUs across bath, body, face, therapeutic, and sleep categories.

GW Pharmaceuticals PLC (NASDAQ:GWPH) just announced that the European Commission (EC) has approved the marketing authorization for EPIDYOLEX for use as adjunctive therapy of seizures associated with Lennox‑Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older. The approval paves the way for the launch of the medicine across Europe.  “The approval of EPIDYOLEX marks a significant milestone, offering patients and their families the first in a new class of epilepsy medicines and the first and only EMA-approved CBD medicine to treat two severe and life-threatening forms of childhood-onset epilepsy,” said Justin Gover, GW’s CEO. “This approval is the culmination of many years of dedication and collaboration between GW, physicians and the epilepsy community. We believe patients and physicians deserve access to rigorously tested and evaluated cannabis-based medicines, manufactured to the highest standards and approved by medicines regulators, and we are delighted to be the first to offer this solution to the epilepsy community.”

Tilray Inc. (NASDAQ:TLRY) announced it has entered into a definitive agreement pursuant to which Tilray, through a wholly-owned subsidiary of High Park Holdings Ltd. (will acquire all of the issued and outstanding securities of 420 Investments Ltd., an adult-use cannabis retail operator headquartered in Calgary, Alberta.  FOUR20 provides adult-use cannabis consumers with a premium retail experience focused on high quality product selection, education and community. FOUR20 currently operates six licensed retail locations and has 16 additional high-traffic locations secured in desirable locations in Alberta, including Canmore, Calgary and Edmonton. Tilray and High Park will leverage FOUR20’s retail expertise and brand and market knowledge to expand into other Canadian provincial markets where Licensed Producer retail ownership will be permitted in the future.  “FOUR20 offers a premium retail experience for the mainstream cannabis consumer and builds on our broader retail strategy, which includes several minority investments in other leading cannabis retailers,” says Tilray Chief Corporate Development Officer Andrew Pucher. “With FOUR20, we will elevate the retail experience for consumers by offering the best quality-tested products while preparing for the next wave of legalized product launches taking place by year’s end.”

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM expects to be compensated three thousand five hundred dollars for news coverage of the current press releases issued by The Yield Growth Corp. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:
Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757

$PBIO Update on Guidance for Revenue Growth, Revolutionary CBD Oil Processing System

• The company believes that its total revenue will more than double in 2020, led by commercialization of its revolutionary CBD oil nanoemulsification system
• PBIO’s BaroShear K45, based on the company’s proprietary Ultra Shear Technology (UST) platform, revolutionizes the manufacture of water-soluble, long-term, stable, highly absorbable, nanoemulsified CBD oil
• The worldwide CBD market is expected to reach $20 billion in sales by 2024, with competition ramping up as CBD manufacturers seek new ways to stand out
• PBIO has announced three pre-sales of its BaroShear K45 nanoemulsification system for making water-soluble CBD Oil
• Progress continues on the build-out of its GMP-compliant manufacturing laboratory to showcase the BaroShear K45 and its industrial scale, high volume UST-based nanoemulsification systems (release date to be determined)

Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, expects its total revenues to more than double in 2020 following the successful launch of its revolutionary CBD (cannabidiol) processing system – the BaroShear K45. This novel processing system creates a water-soluble CBD oil that disperses instantly in liquid, providing enhanced quality and bio-absorption (http://nnw.fm/4fGre).

Development of the BaroShear K45 system began following the company’s in-depth analysis of the CBD market, which showed a common, yet critical production issue facing CBD manufacturers – the poor water solubility of today’s oil-based CBD products means that the beneficial properties of CBD are…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://nnw.fm/PBIO

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$YGYI Announces Closing of Public Offering

SAN DIEGO, Sept. 24, 2019 — Youngevity International, Inc. (NASDAQ:YGYI), a leading multi-channel lifestyle company, today announced the closing of its underwritten public offering of 333,500 shares of its 9.75% Series D Cumulative Redeemable Perpetual Preferred Stock (the “Series D Preferred Stock”) (including 43,500 shares of Series D Preferred Stock pursuant to the exercise of the over-allotment option by the underwriters) at a public offering price of $25.00 per share generating gross proceeds of $8,337,500,  before deducting discount,  commissions and estimated offering expenses.

The Benchmark Company, LLC acted as sole book-running manager of the offering.

The securities described above were offered by the company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-225053) previously filed with the Securities and Exchange Commission (“SEC”) on May 18, 2018, and declared effective on May 29, 2018. The offering was made only by means of a prospectus forming part of the effective registration statement. A final prospectus relating to the securities being offered has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus relating to the offering may be obtained from The Benchmark Company, LLC, Attn: Prospectus Department, 150 E. 58th Street, 17th floor, New York, NY 10155 or by calling 212-312-6700 or by emailing prospectus@benchmarkcompany.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Youngevity International, Inc.

Youngevity International, Inc. (NASDAQ: YGYI), is a multi-channel lifestyle company operating in 3 distinct business segments including a commercial coffee enterprise, a commercial hemp enterprise, and a multi-vertical omni direct selling enterprise.  The Company features a multi country selling network and has assembled a virtual Main Street of products and services under one corporate entity, YGYI offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, as well as innovative services. For investor information, please visit YGYI.com. Be sure to like us on Facebook and follow us on Twitter

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, our ability to drive revenue in our commercial coffee segment,  our ability to develop and grow our hemp commercial segment, our ability to continue our international growth, our ability to leverage our platform and global infrastructure to drive organic growth, our ability  to  return to profitability, expand our liquidity, and strengthen our balance sheet, our ability to continue to maintain compliance with the NASDAQ requirements, the acceptance of the omni-direct approach by our customers, our ability to expand our distribution, our ability to add additional products (whether developed internally or through acquisitions), and the other factors discussed in the prospectus supplement and accompanying base prospectus and our Annual Report on Form 10-K for the year ended December 31, 2018 and our subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

$CNPOF $RIV Opens the Market at Toronto Stock Exchange

$INMB Discusses Company Accomplishments at Nasdaq’s MarketSite

La Jolla, CA., Sept. 24, 2019 —  INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that RJ Tesi, M.D., Co-Founder and CEO will be featured in an interview with multimedia financial reporter, Jason Lin discussing the company’s accomplishments. The interview can be found by clicking here.

“Nasdaq’s MarketSite is a premiere platform for INmune Bio to share our story with investors and to discuss recent developments in our programs for cancer, Alzheimer’s disease and nonalcoholic steatohepatitis (NASH) liver disease,” said Dr. Tesi. “We hope to continue reaching new milestones in the development of therapies that target the innate immune system.”

INmune Bio has four drug development programs: two that are designed to treat cancer, INKmune™ and INB03 — with recently reported positive preliminary data from the Phase 1 trial in patients with advanced cancer; XPro1595 for the treatment of neuroinflammation and Alzheimer’s disease; and NeuLiv™ for the treatment of NASH.

Additionally, CJ Barnum, Ph.D., Director of Neuroscience, will present on “Approaching Alzheimer’s disease as an immunological disease: role of biomarkers” at the World Immunotherapy Congress on Oct. 16 in Switzerland.

About INmune Bio, Inc.
INmune Bio, Inc.  is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms.  The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for cancer (INB03), Alzheimer’s (XPro595), and NASH (NeuLiv). The Innate Immune Priming Platform includes INKmune aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer.  INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INBO3, XPro1595, INKmune and NeuLiv are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact:
David Moss, CFO
(858) 964-3720
DMoss@INmuneBio.com

Media Contact:
Antenna Group
Holly Dugan
(201) 465-8019
INmuneBio@AntennaGroup.com

David Schull
Russo Partners
(212) 845-4271
David.Schull@russopartnersllc.com

$SRAX BIGtoken Platform with Integrated Big Rewards™ Programs

• Major CPG brands Kraft and Sun-Maid partner with SRAX through BIGtoken platform
• BIGtoken continues global expansion, entering the EU market
• SRAX is building what it hails as the most valuable opted-in data set in the world

SRAX Inc. (NASDAQ: SRAX) is a digital marketing and consumer data management technology company that integrates all aspects of the advertising experience, including verified consumer participation, to deliver a digital competitive advantage for brands across multiple industries. The company is building additional value by empowering consumers to own and earn from their data through its consumer data management and distribution system, BIGtoken. Recently, major consumer packaged goods (CPG) brands Kraft (NASDAQ: KHC) and Sun-Maid launched programs on the BIGtoken platform, validating that marketers are interested in reaching consumers who have opted into being rewarded for their data. Both marketers are gifting consumers with BIGtoken points for making purchases of their products at Walmart (NYSE: WMT).

In a revolutionary new way to reward consumers, BIGtoken poses a few survey questions and then asks customers to scan their receipt with image recognition technology, which is built into the BIGtoken platform. Once this is done, the consumer is rewarded, and the marketer has…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$INMB to Present XPro1595 for Treating Neuroinflammation in Alzheimer’s Disease at AAIC

LA JOLLA, Calif., Sept. 23, 2019 — INmune Bio, Inc. (NASDAQ: INMB), an immunotherapy company developing treatments which harness the patient’s innate immune system to fight disease, announced today that the company will be presenting at the upcoming Alzheimer’s Association International Conference (AAIC) Satellite Symposium held Sept. 25 – 27 in Sydney, Australia.

C.J. Barnum, Ph.D., Director of Neuroscience at INmune Bio, will present the company’s strategy for treating Alzheimer’s disease at a panel session, along with other global researchers and leaders in the latest therapeutics and developments in Alzheimer’s clinical research.

“Neuroinflammation is now widely recognized as a key therapeutic target in Alzheimer’s disease,” said Dr. Barnum. “ We believe that neuroinflammation plays a critical role in neurologic disorders like Alzheimer’s and our drug candidate, XPro1595 is starting clinical trials to test this hypothesis.”

AAIC is the premier annual conference for presentation and discussion of the latest Alzheimer’s and dementia research. The AAIC Satellite Symposium is part of the events organized by the Alzheimer’s Association and gathers researchers from around the world to discuss scientific advances in the understanding and treatment of Alzheimer’s disease and other related dementias. Dr. Barnum will present during a panel session moderated by Malú Tansey, Ph.D., Professor of Neuroscience and Director of the Center for Translational Research in Neurodegenerative Disease at the University of Florida College of Medicine.

Session 3:  Therapeutics: State of the Field

Presentation Title: A Biomarker-Directed Approach to Targeting Inflammation in Alzheimer’s Patients

Time and Date: 5:10 PM – 5:30 PM, Sept. 25

Location: Hyatt Regency Sydney, Australia

Alzheimer’s disease is a progressive neurodegenerative disease that is the most common cause of dementia and is characterized by the decline in cognitive function and neuronal loss. Sustained activation of the brain’s resident macrophages (microglia) and other immune cells have emerged as the underlying pathological condition that facilitates and exacerbates the progression of the disease. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website.

About the Alzheimer’s Association

The Alzheimer’s Association is the leading voluntary health organization in Alzheimer’s care, support and research. Its mission is to eliminate Alzheimer’s disease through the advancement of research; to provide and enhance care and support for all affected, and to reduce the risk of dementia through the promotion of brain health. Its vision is a world without Alzheimer’s. Visit the Alzheimer’s Association website or call 800.272.3900.

About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms.  The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dyfunction and mechanistic target of many diseases. DN-TNF is currently being developed for cancer (INB03), Alzheimers (XPro595), and NASH (NeuLiv). The Innate Immune Priming Platform includes INKmune aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer.  INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INBO3 and XPro1595 are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact:
David Moss, CFO
(858) 964-3720
DMoss@INmuneBio.com

Media Contact:
David Schull
Russo Partners
(212) 845-4271
David.Schull@russopartnersllc.com

$YGYI Announces Pricing of $7.25M Underwritten Public Offering